57 related articles for article (PubMed ID: 38661301)
1. Response to Letter Regarding Article, The Role of COVID-19 Vaccination for Patients With Atherosclerotic Cardiovascular Disease in the Upcoming Endemic Era.
Kim KH
J Lipid Atheroscler; 2024 May; 13(2):213-214. PubMed ID: 38826177
[No Abstract] [Full Text] [Related]
2. Letter by Hinpetch Daungsupawong Regarding Article, The Role of COVID-19 Vaccination for Patients With Atherosclerotic Cardiovascular Disease in the Upcoming Endemic Era.
Daungsupawong H; Wiwanitkit V
J Lipid Atheroscler; 2024 May; 13(2):212. PubMed ID: 38826185
[No Abstract] [Full Text] [Related]
3. Effectiveness of vaccination against SARS-CoV-2 and the need for alternative preventative approaches in immunocompromised individuals: a narrative review of systematic reviews.
Tan TT; Ng HJ; Young B; Khan BA; Shetty V; Azmi N; Clissold S
Expert Rev Vaccines; 2023; 22(1):341-365. PubMed ID: 36920116
[TBL] [Abstract][Full Text] [Related]
4. Immunocompromised individuals are at increased risk of COVID-19 breakthrough infection, hospitalization, and death in the post-vaccination era: A systematic review.
Bytyci J; Ying Y; Lee LYW
Immun Inflamm Dis; 2024 Apr; 12(4):e1259. PubMed ID: 38661301
[TBL] [Abstract][Full Text] [Related]
5. Effectiveness of 2-Dose Vaccination with mRNA COVID-19 Vaccines Against COVID-19-Associated Hospitalizations Among Immunocompromised Adults - Nine States, January-September 2021.
Embi PJ; Levy ME; Naleway AL; Patel P; Gaglani M; Natarajan K; Dascomb K; Ong TC; Klein NP; Liao IC; Grannis SJ; Han J; Stenehjem E; Dunne MM; Lewis N; Irving SA; Rao S; McEvoy C; Bozio CH; Murthy K; Dixon BE; Grisel N; Yang DH; Goddard K; Kharbanda AB; Reynolds S; Raiyani C; Fadel WF; Arndorfer J; Rowley EA; Fireman B; Ferdinands J; Valvi NR; Ball SW; Zerbo O; Griggs EP; Mitchell PK; Porter RM; Kiduko SA; Blanton L; Zhuang Y; Steffens A; Reese SE; Olson N; Williams J; Dickerson M; McMorrow M; Schrag SJ; Verani JR; Fry AM; Azziz-Baumgartner E; Barron MA; Thompson MG; DeSilva MB
MMWR Morb Mortal Wkly Rep; 2021 Nov; 70(44):1553-1559. PubMed ID: 34735426
[TBL] [Abstract][Full Text] [Related]
6. Comparative effectiveness of mRNA-1273 and BNT162b2 COVID-19 vaccines in immunocompromised individuals: a systematic review and meta-analysis using the GRADE framework.
Wang X; Haeussler K; Spellman A; Phillips LE; Ramiller A; Bausch-Jurken MT; Sharma P; Krivelyova A; Vats S; Van de Velde N
Front Immunol; 2023; 14():1204831. PubMed ID: 37771594
[TBL] [Abstract][Full Text] [Related]
7. Immunological and clinical efficacy of COVID-19 vaccines in immunocompromised populations: a systematic review.
Galmiche S; Luong Nguyen LB; Tartour E; de Lamballerie X; Wittkop L; Loubet P; Launay O
Clin Microbiol Infect; 2022 Feb; 28(2):163-177. PubMed ID: 35020589
[TBL] [Abstract][Full Text] [Related]
8. COVID-19: Third dose booster vaccine effectiveness against breakthrough coronavirus infection, hospitalisations and death in patients with cancer: A population-based study.
Lee LYW; Ionescu MC; Starkey T; Little M; Tilby M; Tripathy AR; Mckenzie HS; Al-Hajji Y; Appanna N; Barnard M; Benny L; Burnett A; Cattell EL; Clark JJ; Khan S; Ghafoor Q; Panneerselvam H; Illsley G; Harper-Wynne C; Hattersley RJ; Lee AJ; Lomas O; Liu JK; McCauley A; Pang M; Pascoe JS; Platt JR; Patel G; Patel V; Potter VA; Randle A; Rigg AS; Robinson TM; Roques TW; Roux RL; Rozmanowski S; Taylor H; Tuthill MH; Watts I; Williams S; Beggs A; Iveson T; Lee SM; Middleton G; Middleton M; Protheroe A; Fittall MW; Fowler T; Johnson P;
Eur J Cancer; 2022 Nov; 175():1-10. PubMed ID: 36084618
[TBL] [Abstract][Full Text] [Related]
9. Effects of Antibody Response after Booster Vaccination on SARS-CoV-2 Breakthrough Infections and Disease Outcomes in Advanced Cancer Patients: A Prospective Analysis of the Vax-on-Third Study.
Nelli F; Fabbri A; Virtuoso A; Giannarelli D; Giron Berrios JR; Marrucci E; Fiore C; Schirripa M; Signorelli C; Chilelli MG; Primi F; Pessina G; Natoni F; Silvestri MA; Ruggeri EM
Curr Oncol; 2023 May; 30(5):5103-5115. PubMed ID: 37232844
[TBL] [Abstract][Full Text] [Related]
10. Risk factors identification of COVID-19 patients with chronic obstructive pulmonary disease: A retrospective study in Punjab-Pakistan.
Hassan MM; Tahir MH; Ameeq M; Jamal F; Mendy JT; Chesneau C
Immun Inflamm Dis; 2023 Aug; 11(8):e981. PubMed ID: 37647450
[TBL] [Abstract][Full Text] [Related]
11. Outcome of COVID-19 in hospitalised immunocompromised patients: An analysis of the WHO ISARIC CCP-UK prospective cohort study.
Turtle L; Thorpe M; Drake TM; Swets M; Palmieri C; Russell CD; Ho A; Aston S; Wootton DG; Richter A; de Silva TI; Hardwick HE; Leeming G; Law A; Openshaw PJM; Harrison EM; ; Baillie JK; Semple MG; Docherty AB
PLoS Med; 2023 Jan; 20(1):e1004086. PubMed ID: 36719907
[TBL] [Abstract][Full Text] [Related]
12. Prevalence of covid-19 among patients with chronic obstructive pulmonary disease and tuberculosis.
Muneeb Hassan M; Ameeq M; Jamal F; Tahir MH; Mendy JT
Ann Med; 2023 Dec; 55(1):285-291. PubMed ID: 36594409
[TBL] [Abstract][Full Text] [Related]
13. Severe COVID-19 outcomes after full vaccination of primary schedule and initial boosters: pooled analysis of national prospective cohort studies of 30 million individuals in England, Northern Ireland, Scotland, and Wales.
Agrawal U; Bedston S; McCowan C; Oke J; Patterson L; Robertson C; Akbari A; Azcoaga-Lorenzo A; Bradley DT; Fagbamigbe AF; Grange Z; Hall ECR; Joy M; Katikireddi SV; Kerr S; Ritchie L; Murphy S; Owen RK; Rudan I; Shah SA; Simpson CR; Torabi F; Tsang RSM; de Lusignan S; Lyons RA; O'Reilly D; Sheikh A
Lancet; 2022 Oct; 400(10360):1305-1320. PubMed ID: 36244382
[TBL] [Abstract][Full Text] [Related]
14. Risk of Severe COVID-19 Outcomes Among Patients with Immune-Mediated Inflammatory Diseases or Malignancies: A Retrospective Analysis of Real-World Data in the United States.
Yue X; Ye Y; Choi YC; Zhang D; Krueger WS
Adv Ther; 2022 Dec; 39(12):5413-5432. PubMed ID: 36153800
[TBL] [Abstract][Full Text] [Related]
15.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
